{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T20:35:38Z","timestamp":1776285338683,"version":"3.50.1"},"reference-count":34,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FEDER\u2014Fundo Europeu de Desenvolimento Regional","award":["UIDB\/4255\/2020"],"award-info":[{"award-number":["UIDB\/4255\/2020"]}]},{"name":"FEDER\u2014Fundo Europeu de Desenvolimento Regional","award":["\u201cRISE\u2014LA\/P\/0053\/2020"],"award-info":[{"award-number":["\u201cRISE\u2014LA\/P\/0053\/2020"]}]},{"name":"FEDER\u2014Fundo Europeu de Desenvolimento Regional","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]},{"name":"Portuguese funds","award":["UIDB\/4255\/2020"],"award-info":[{"award-number":["UIDB\/4255\/2020"]}]},{"name":"Portuguese funds","award":["\u201cRISE\u2014LA\/P\/0053\/2020"],"award-info":[{"award-number":["\u201cRISE\u2014LA\/P\/0053\/2020"]}]},{"name":"Portuguese funds","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]},{"name":"FCT","award":["UIDB\/4255\/2020"],"award-info":[{"award-number":["UIDB\/4255\/2020"]}]},{"name":"FCT","award":["\u201cRISE\u2014LA\/P\/0053\/2020"],"award-info":[{"award-number":["\u201cRISE\u2014LA\/P\/0053\/2020"]}]},{"name":"FCT","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]},{"name":"FEDER","award":["UIDB\/4255\/2020"],"award-info":[{"award-number":["UIDB\/4255\/2020"]}]},{"name":"FEDER","award":["\u201cRISE\u2014LA\/P\/0053\/2020"],"award-info":[{"award-number":["\u201cRISE\u2014LA\/P\/0053\/2020"]}]},{"name":"FEDER","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]},{"name":"CHAIR in Onco-Innovation at FMUP","award":["UIDB\/4255\/2020"],"award-info":[{"award-number":["UIDB\/4255\/2020"]}]},{"name":"CHAIR in Onco-Innovation at FMUP","award":["\u201cRISE\u2014LA\/P\/0053\/2020"],"award-info":[{"award-number":["\u201cRISE\u2014LA\/P\/0053\/2020"]}]},{"name":"CHAIR in Onco-Innovation at FMUP","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Dostarlimab (JEMPERLI) is a PD-1 monoclonal antibody for the treatment of adult patients, with mismatch repair deficient (dMMR), recurrent or advanced endometrial cancer that has progressed on or following prior therapy with a platinum-containing regimen. As determined by an FDA-approved test this indication was granted rapid approval based on the rate of tumor response and the duration of the response. Continued approval for this indication is conditioned on further confirmatory trials demonstrating and documenting clinical benefit. In June 2022, the clinical trial NCT04165772 reported a 100% remission rate for rectal cancer. This clinical trial brought proof that we can match a tumor and the genetics of what is driving it, with therapy. This clinical trial continues to enroll patient and is currently enrolling patients with gastric, prostate, and pancreatic cancers. Dostarlamib is being recommended for rectal cancer. The focus of this review is to summarize the existing knowledge regarding Dostarlimab and explore the possibilities of mono- and combination therapies.<\/jats:p>","DOI":"10.3390\/biom12081031","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T22:03:42Z","timestamp":1658873022000},"page":"1031","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Dostarlimab: A Review"],"prefix":"10.3390","volume":"12","author":[{"given":"B\u00e1rbara","family":"Costa","sequence":"first","affiliation":[{"name":"OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[{"name":"OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"key":"ref_1","first-page":"747","article-title":"Immunotherapy Through the Years","volume":"8","author":"Eno","year":"2017","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1208\/s12248-020-00514-4","article-title":"Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors","volume":"22","author":"Gjoerup","year":"2020","journal-title":"AAPS J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"173240","DOI":"10.1016\/j.ejphar.2020.173240","article-title":"Regulation of PD-1 in T Cells for Cancer Immunotherapy","volume":"881","author":"Yu","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1954136","DOI":"10.1080\/19420862.2021.1954136","article-title":"Preclinical Characterization of Dostarlimab, a Therapeutic Anti-PD-1 Antibody with Potent Activity to Enhance Immune Function in in Vitro Cellular Assays and in Vivo Animal Models","volume":"13","author":"Kumar","year":"2021","journal-title":"MAbs"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7688","DOI":"10.1074\/jbc.M112.445502","article-title":"Humanization of Antibodies Using Heavy Chain Complementarity-Determining Region 3 Grafting Coupled with in Vitro Somatic Hypermutation","volume":"288","author":"Bowers","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbrc.2022.02.026","article-title":"Molecular Basis of PD-1 Blockade by Dostarlimab, the FDA-Approved Antibody for Cancer Immunotherapy","volume":"599","author":"Park","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00280-021-04358-3","article-title":"Safety, Antitumor Activity, and Pharmacokinetics of Dostarlimab, an Anti-PD-1, in Patients with Advanced Solid Tumors: A Dose\u2013Escalation Phase 1 Trial","volume":"89","author":"Patnaik","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1208\/s12248-021-00624-7","article-title":"An Integrated Analysis of Dostarlimab Immunogenicity","volume":"23","author":"Lu","year":"2021","journal-title":"AAPS J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/s41419-020-03173-7","article-title":"Quantifying the Efficacy of Checkpoint Inhibitors on CD8+ Cytotoxic T Cells for Immunotherapeutic Applications via Single-Cell Interaction","volume":"11","author":"Sullivan","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s40265-021-01539-5","article-title":"Dostarlimab: First Approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination Strategies with PD-1\/PD-L1 Blockade: Current Advances and Future Directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_13","unstructured":"CHMP (2022, June 20). Committee for Medicinal Products for Human Use (CHMP) Assessment Report. Available online: https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2021."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e003924","DOI":"10.1136\/jitc-2021-003924","article-title":"IOLite: Phase 1b Trial of Doublet\/Triplet Combinations of Dostarlimab with Niraparib, Carboplatin-Paclitaxel, with or without Bevacizumab in Patients with Advanced Cancer","volume":"10","author":"Yap","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_15","first-page":"4421","article-title":"Population Pharmacokinetics and Exposure\u2013Response of Anti-Programmed Cell Death Protein-1 Monoclonal Antibody Dostarlimab in Advanced Solid Tumours","volume":"87","author":"Melhem","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_16","unstructured":"CHMP (2022, June 20). ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/annex-i-summary-product-characteristics_en.pdf."},{"key":"ref_17","unstructured":"U.S. Food and Drug Administration (2022, June 20). JEMPERLI Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761174s000lbl.pdf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2217\/fon-2020-0655","article-title":"Dostarlimab in the Treatment of Recurrent or Primary Advanced Endometrial Cancer","volume":"17","author":"Kasherman","year":"2021","journal-title":"Futur. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.18632\/oncotarget.13895","article-title":"PD-1 and Its Ligands Are Important Immune Checkpoints in Cancer","volume":"8","author":"Dong","year":"2017","journal-title":"Oncotarget"},{"key":"ref_20","first-page":"1","article-title":"Immunogenicity of Immunomodulatory, Antibody-Based, Oncology Therapeutics. J. Immunother","volume":"7","author":"Davda","year":"2019","journal-title":"Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-98700-7","article-title":"Identification of Neutralising Pembrolizumab Anti-Drug Antibodies in Patients with Melanoma","volume":"11","author":"Sasson","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e003777","DOI":"10.1136\/jitc-2021-003777","article-title":"Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient\/microsatellite instability-high (dMMR\/MSI-H) or proficient\/stable (MMRp\/MSS) endometrial cancer: Interim results from GARNET\u2014A phase I, single-arm study","volume":"10","author":"Oaknin","year":"2002","journal-title":"J. Immunother. Cancer"},{"key":"ref_23","first-page":"727","article-title":"PD-1\/PD-L1 Pathway: Current Researches in Cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S1470-2045(17)30512-0","article-title":"PD-1 inhibition in metastatic dMMR\/MSI-H colorectal cancer","volume":"18","author":"Sclafani","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.2217\/fon-2020-1269","article-title":"Belantamab Mafodotin in Combination with Novel Agents in Relapsed\/Refractory Multiple Myeloma: DREAMM-5 Study Design","volume":"17","author":"Nooka","year":"2021","journal-title":"Future Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1136\/ijgc-2021-002593","article-title":"Randomized Phase III Trial on Niraparib-TSR-042 (Dostarlimab) versus Physician\u2019s Choice Chemotherapy in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment: NItCHE Trial (MITO 33)","volume":"31","author":"Musacchio","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1358\/dot.2021.57.3.3233363","article-title":"Dostarlimab for the Treatment of Endometrium Cancer and Other Solid Tumors","volume":"57","author":"Doger","year":"2021","journal-title":"Drugs Today"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00292-021-00948-3","article-title":"MSI Testing: What\u2019s New? What Should Be Considered?","volume":"42","author":"Baretton","year":"2021","journal-title":"Pathologe"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch Repair Deficiency Predicts Response of Solid Tumors to PD-1 Blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"880008","DOI":"10.3389\/fonc.2022.880008","article-title":"Management of Metastatic Endometrial Cancer: Physicians\u2019 Choices Beyond the First Line. A MITO Survey","volume":"12","author":"Giannone","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1001\/jamaoncol.2020.4515","article-title":"Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients with Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial","volume":"6","author":"Oaknin","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17512433.2022.2044791","article-title":"Dostarlimab for the Treatment of Advanced Endometrial Cancer","volume":"15","author":"Redondo","year":"2022","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"100442","DOI":"10.1016\/j.ctarc.2021.100442","article-title":"Immunotherapy in Colorectal Cancer: Is the Long-Awaited Revolution Finally Happening?","volume":"28","author":"Arrichiello","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Sartore-Bianchi, A., Agostara, A.G., Patelli, G., Mauri, G., Pizzutilo, E.G., and Siena, S. (Dig. Liver Dis., 2022). Application of Histology-Agnostic Treatments in Metastatic Colorectal Cancer, Dig. Liver Dis., in press.","DOI":"10.1016\/j.dld.2022.05.013"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/8\/1031\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:56:59Z","timestamp":1760140619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/8\/1031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["biom12081031"],"URL":"https:\/\/doi.org\/10.3390\/biom12081031","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]}}}